Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO GU 2023 HIGHLIGHTS
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
By
Anne Rowe
ASCO GU 2023 HIGHLIGHTS
,
Prostate Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease and should be considered the new standard of care for this patient population.
Read Article
Addressing Health Equity in Bladder Cancer Care
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
,
Bladder Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
Read Article
What Will It Take to End Cancer As We Know It?
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
April 2023, Vol 14, No 2
In his keynote address at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, Norman E. “Ned” Sharpless, MD, Former Director of the National Cancer Institute, and Professor, Cancer Policy and Innovation, University of North Carolina School of Medicine, Chapel Hill, told attendees that although cancer-related mortality is declining, challenges remain to “end cancer as we know it.”
Read Article
Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
,
Renal-Cell Carcinoma
,
Genitourinary Cancers
April 2023, Vol 14, No 2
The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma